After being treated for his chronic lymphocytic leukemia with chimeric antigen receptor (CAR) T-cell therapy, Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society, is being followed for 15 years to better understand if there are any undiscovered adverse events that pop up and how durable the response is.
After being treated for his chronic lymphocytic leukemia with chimeric antigen receptor (CAR) T-cell therapy, Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society, is being followed for 15 years to better understand if there are any undiscovered adverse events that pop up and how durable the response is.
Transcript
As someone treated with CAR T cells, what do you do regarding follow up? What is your physician keeping an eye out for?
Since CAR T is a new therapy, and the first genetic therapy that’s been approved in the United States by the FDA, I’m being followed for 15 years. Which I’m very happy about, because if I’m being followed for 15 years, that will mean I’m 82 years old, so it means I’ve lived 15 years with this.
I’m being followed to see are there any undiscovered adverse events that we don’t know about. It is gene therapy, I have foreign genes in my body, that’s why it’s a chimera—a mix of 2 different creatures in me. So, I have foreign protein in me. Is this going to cause a problem? Other gene therapies have been disastrous in the past. So far with CAR T things have gone well. But is there something that’s going to pop up 5 years from now, 10 years from now? We really don’t know the answer to that. So, that’s one thing that I’m being looked at for.
The other thing is how persistent are the CAR T cells, themselves? There’s not clarity on how important that is in terms of the duration of the response. So, some people lose their CAR Ts and they still have very durable responses, and other people have persistent CAR Ts, but the cancer comes back.
And that leads to the other big question: do I remain in a complete response? Or is the cancer creeping back again? That’s the main thing that they want. So, in CLL, the responses have tended to be quite durable for most patients. But in other blood cancers, sometimes people get a deep response—MRD [minimal residual disease] undetectable—but the disease can be back again in 6 months. So, I think that those are the things that they’re looking for.
Plus, the usual kind of things. Am I getting more infections, am I getting anemic, am I getting problems with my platelets? Things like that. The follow-up isn’t too onerous. I essentially get a physical exam and blood work once a year.
Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say
May 12th 2025Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising therapeutic target. But investigators involved in TIGIT studies say the problem is finding the right biomarker.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Community Oncology Reacts to Trump's Drug Pricing Executive Order
May 2nd 2025An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.
Read More